---
url: https://www.servicesaustralia.gov.au/ulcerative-colitis-toxicity-and-severity-descriptors
title: Ulcerative colitis toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:44:08.264Z
source: servicesaustralia.gov.au
---
# Ulcerative colitis toxicity and severity descriptors

Toxicity criteria and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat ulcerative colitis.

## on this page

-   [Prednisolone](#a1)
-   [Azathioprine](#a2)
-   [Mercaptopurine](#a3)
-   [5-aminosalicylates](#a4)

ADL - activities of daily living  
NIH - National Institutes of Health  
LLN - lower limit of normal  
ULN - upper limit of normal

## Prednisolone

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastro-intestinal**

Gastric irritation/ulcer

Requiring medical management

2 (or higher)

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Weight gain

≥ 20% weight gain

3 (or higher)

**Cardiovascular**

Hypertension

Requiring therapy or more intensive therapy than previously

3 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Central nervous system - past psychiatric history not a contraindication**

Insomnia

Frequent insomnia interfering with ADL

3 (or higher)

Mood alteration

Severe mood alteration interfering with ADL

3 (or higher)

Personality/behavioural

Disruptive to patient/family, requiring mental health intervention

3 (or higher)

Restlessness

Severe

3 (or higher)

**Dermatological**

Acne/dermatological conditions

Severe

3 (or higher)

Purpura/bruising

Generalised or mucosal petechiae

3 (or higher)

Impaired healing

Requiring medical management

2 (or higher)

**Laboratory**

Hyperglycaemia

Glucose 13.9 mmol/L or higher

3 (or higher)

Hypertriglyceridemia

\> 5-10 x ULN

3 (or higher)

Hypokalaemia

< 3.0 mmol/L

3 (or higher)

**Endocrine**

Cushingoid appearance

Present

3 (or higher)

Disordered menstruation

Very irregular over pre-treatment

2 (or higher)

**Ocular**

Cataracts

Symptomatic visual loss requiring treatment or interfering with function

3 (or higher)

Glaucoma

Increase in intraocular pressure with retinal changes

2 (or higher)

**Musculoskeletal**

Osteoporosis/fracture

Symptomatic, interfering with ADL

 

Avascular necrosis

Symptomatic, interfering with function

2 (or higher)

Myopathy

Symptomatic, interfering with function

2 (or higher)

**Miscellaneous**

Immuno-suppression

Severe, requiring treatment withdrawal

3 (or higher)

Impaired healing

Symptomatic, interfering with ADL

 

Growth retardation

 

 

## Azathioprine

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Haematological**

Leucocytes

< 2 x 109 / L

3 (or higher)

Haemoglobin

< 80 g/L

3 (or higher)

Thrombocytes

< 50 x 109 / L

3 (or higher)

**Neoplasms**

New malignancy

Serious malignancy present

4

**Gastro-intestinal**

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Diarrhoea

Increase of more than 4 stools per day over pre-treatment or incontinence

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but can eat/swallow

2 (or higher)

Abdominal pain

Severe pain/analgesia interfering with ADL

3 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

**Hepatic**  

Bilirubin

\> 1.5 x ULN

2 (or higher)

Hepatic enzymes

\> 2.5 x ULN

2(or higher)

**Dermatological**

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

Alopecia

Pronounced hair loss

3 (or higher)

**Pulmonary**  

Pneumonitis

X-ray changes, requiring steroids and diuretics

2 (or higher)

**Miscellaneous**

Hypersensitivity

Rash, drug fever > 380, aches etc.

2 (or higher)

Immuno-suppression/atypical infection

Severe/systemic infection requiring IV antibiotic/antifungal treatment or hospitalisation

3 (or higher)

## Mercaptopurine

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Haematological**

Leucocytes

< 2 x 109 / L

3 (or higher)

Haemoglobin

< 80 g/ L

3 (or higher)

Thrombocytes

< 50 x 109 / L

3 (or higher)

**Gastro-intestinal**   

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Anorexia

Oral intake significantly reduced

2 (or higher)

Stomatitis (oral ulcers etc.)

Painful erythema, oedema or ulcers but can eat/swallow

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Hepatic enzymes

\> 2.5 x ULN

2 (or higher)

**Dermatological**

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

Alopecia

Pronounced hair loss

3 (or higher)

**Neoplasia**

Secondary malignancy (e.g. leukaemia)

Present

4

**Miscellaneous**

Hypersensitivity

Rash, drug fever > 38°C, arthralgia etc.

2 (or higher)

Joint pain

Moderate pain/analgesics, significantly interferes with function

2 (or higher)

## 5-aminosalicylates

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood / Bone Marrow**

Anaemia

Haemoglobin < 80 g/L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 / L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 / L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 / L

3 (or higher)

**Dermatology / Skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash / desquamation

Scattered macular or papular eruption or erythema **with pruritus or other associated symptoms** covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools/day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT and/or AST > 2.5 x ULN **or** ALT and/or AST > 1.5 x ULN on three occasions over a 3-month period

2 (or higher)

^Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Neurology / Senses**

Headaches (severe)

Severe pain: pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Neuropathy - Sensory

Objective sensory loss or paraesthesia interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

**Pulmonary** 

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment.

3 (or higher)

Pneumonitis/pulmonary infiltrates

Radiographic changes, Respiratory Function Test abnormalities and requiring steroids or diuretics

2 (or higher)

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Proteinuria

\> 1.0g/24 hours, elevated urine protein/creatinine ratios, (dipstick protein ++ or greater), confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL/min

2 (or higher)

**Other** 

Allergic reaction

Urticaria, drug fever > 38°C and / or bronchospasm

2 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39°C (oral or tympanic)

2 (or higher)
